CBIS法を用いたマルチアプリケーションな抗CD20抗体の樹立

• Published in: 日本薬理学会年会要旨集 p. 1-O-004
• Main Authors: 古澤, 慶一, 金子, 美華, 三輪, 崇志, 福井, 真人, 加藤, 幸成
• Format: Journal Article
• Language: Japanese
• Published: 公益社団法人 日本薬理学会 2020
• Subjects: antibody
• ISSN: 2435-4953
• DOI: 10.1254/jpssuppl.93.0_1-O-004

Purpose: CD20 is one of B-lymphocyte antigens, and is known as an effective target for B cell lymphomas. Although anti-CD20 monoclonal antibody (mAb) drugs have brought significant survival benefits to B cell lymphoma patients, some patients have shown no clinical response in a second treatment of anti-CD20 mAbs; therefore, more effective treatment of B cell lymphomas should be developed. In this study, we aimed to develop useful anti-CD20 mAbs for treatment or research of B cell lymphoma. Methods: For the anti-CD20 mAb development, we used Cell-Based Immunization and Screening (CBIS) method. CD20-overexpressed LN229 cells (LN229/CD20) were used for immunization. The screening of hybridomas was performed by flow cytometry (FCM) using CD20-overexpressed CHO cells. Results: We used 8 Balb/c mice for the hybridoma development, and obtained 18 anti-CD20 mAbs. Of those clones, C20Mab-11 (IgM, kappa) was shown to be useful for FCM and western blot (WB) for endogenous CD20-expressing cell lines. Furthermore, C20Mab-11 strongly stained B cells of the lymph follicle via immunohistochemistry (IHC). Conclusion: Using CBIS method, we successfully developed a sensitive and specific anti-CD20 mAb C20Mab-11, which is useful for FCM, WB, and IHC.